Prostate Health Market 2025-2034 Industry Growth Analysis
The Global Prostate Health Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Prostate Health market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.
Browse for Full Report at @ https://www.thebrainyinsights.com/report/prostate-health-market-13309
I cite multiple reputable market estimates because different vendors use different scopes (diagnostics + therapeutics + devices + supplements vs narrower definitions). The five most load-bearing references appear inline next to the main market figures and company datapoints.
Market snapshot (select reputable estimates)
Future Market Insights: Prostate Health Market — USD 46.03 billion in 2025, projected to USD 108.97 billion by 2035 (CAGR ≈ 9%).
InsightAce / Research summary: Global prostate health market USD 36.5 billion (2024) → USD 91.9 billion by 2034 (CAGR ~9.8%).
Grand View / Diagnostics-focused: Prostate cancer diagnostics market estimates vary — for example Grand View reports the prostate-cancer diagnostics market moving toward ~USD 13.16B by 2030 (6.4% CAGR for a diagnostics scope).
GlobalNews / Spherical Insights (alternate): USD 32.6B (2023) → USD 78.03B by 2033 (CAGR 9.12%).
Supplement / urology subsegments: Verified / Grand View estimate for prostate/urology supplements around USD 1.5–1.9B (2024) for supplement-specific markets (saw palmetto, herbal compounds).
(Use the first two rows if you want a broad “prostate health” market that includes drugs, diagnostics, devices and supplements; use the diagnostics-specific numbers when you want PSA/genomics/biopsy/MRI submarket sizing.)
Recent developments
Blockbuster oncology drugs driving revenue: Astellas/Pfizer’s XTANDI (enzalutamide) remains a top prostate cancer therapy (Astellas reports XTANDI sales ≈ ¥912.3 billion in FY2024 — ~JPY figure shown in Astellas FY2024 reporting).
Newer agents / launches: Bayer’s darolutamide (Nubeqa) grew rapidly (reported sales ~€869M in 2023 and Bayer projected ≥$1B in 2024), marking it as a growing blockbuster in prostate cancer therapy.
Genomic & ctDNA diagnostics expanding: Veracyte’s Decipher test and Natera’s Signatera ctDNA solutions have expanded clinical use and revenue — Veracyte reported testing revenue growth (e.g., testing revenue $107–122M quarter-level ranges in 2024–Q1 2025 driven by Decipher). Genomic assays are being adopted for risk stratification and treatment personalization.
Minimally invasive device uptake: Urology device makers (Boston Scientific — Rezūm, Teleflex — UroLift portfolio via Neotract/Teleflex) reported strong procedure growth and are expanding BPH-device adoption in-office/hybrid settings. Boston Scientific reported FY2024 net sales ~$16.747B, with prostate-health product lines (Rezum) showing double-digit growth. Teleflex reported FY2024 revenue ~$3,047.3M (Teleflex lists UroLift in its high-growth portfolio).
Drivers
Aging male population and higher prostate disease incidence (BPH & prostate cancer).
Broader screening and early-detection uptake (PSA testing, MRI, genomic tests) and guideline updates that expand testing in defined groups.
Therapeutic innovation (next-gen androgen-receptor inhibitors, combination regimens)—driving drug-sales growth and market focus.
Restraints
Fragmented market definitions and variable reimbursement (especially for advanced genomic/ctDNA tests and newer devices).
Screening controversies (overdiagnosis / overtreatment concerns with PSA) that affect uptake in some geographies.
High cost of new oncology drugs and country-by-country payer restrictions limiting uptake.
Regional segmentation analysis
North America: Historically the largest spender (high screening rates, early adoption of genomic tests and devices).
Europe: Strong diagnostics and device uptake but heterogeneous reimbursement per country.
Asia-Pacific: Fastest growth potential (aging populations, rising access to diagnostics and branded oncology therapies, expanding private-pay markets).
Emerging trends
Genomic classifiers & ctDNA (Decipher, Signatera and others) moving from prognostics into routine treatment planning and MRD monitoring.
Hybrid care & office-based procedures for BPH (water-vapor therapy, implantable devices) that shorten recovery and shift procedures out of OR settings.
Combination regimens and lifecycle management for existing androgen-axis inhibitors (label expansions and earlier-stage use).
Top use cases
Screening & early detection (PSA plus reflex multimodal triage: MRI/biopsy/genomic tests).
Risk stratification / treatment decisioning for localized prostate cancer (genomic tests).
Advanced prostate cancer therapy (mCRPC systemic drugs — XTANDI, Nubeqa, others).
BPH symptom management (minimally invasive surgical therapies and medical therapies).
Major challenges
Demonstrating cost-effectiveness to payers (especially for expensive drugs and newer genomic/ctDNA assays).
Managing overdiagnosis from population screening and aligning practice guidelines across geographies.
Attractive opportunities
Integration of diagnostics + therapeutics (companion diagnostics, genomic stratification to target high-value therapy).
MRD (ctDNA) monitoring to tailor therapy duration and detect recurrence earlier (Natera/Signatera deployments).
Device expansion into office settings (lower-cost in-office BPH procedures) and growing adoption in emerging markets.
Key factors of market expansion
Reimbursement decisions for advanced diagnostics and drugs; broader guideline endorsements for precision tools; aging demographics; and price/access dynamics for novel therapeutics.
Companies — concrete datapoints (company → value / fact → source)
(Only crisp, citable numbers from company reports, press coverage or high-quality market houses.)
| Company / product | Concrete datapoint (value) | Source |
|---|---|---|
| Future Market Insights (market) | Prostate Health Market: USD 46.03B (2025) → USD 108.97B (2035) (CAGR ≈ 9%). | |
| InsightAce / Global estimate | Global prostate health market: USD 36.5B (2024) → USD 91.9B (2034). | |
| Grand View Research (diagnostics) | Prostate cancer diagnostics forecast example: ~USD 13.16B by 2030 (diagnostics-focused projection; 6.4% CAGR). | |
| Astellas / Pfizer — XTANDI (enzalutamide) | **XTANDI sales reported by Astellas: ≈ ¥912.3 billion (FY2024) —**Astellas FY2024 financials list XTANDI as a strategic-brand revenue driver. (Astellas corporate filings / PDFs). | |
| Bayer / Orion — Nubeqa (darolutamide) | Nubeqa sales ~€869M (2023); Bayer reported expectations for ≥ $1B in 2024 (company statements / Reuters). | |
| Veracyte — Decipher Prostate (genomic test) | Veracyte reported robust testing revenue growth driven by Decipher; e.g., testing revenue: $107.3M (Q1 2025) and quarterly testing revenue of $115–122M reported across 2024–2025 results. | |
| Natera — Signatera (ctDNA) | Natera commercializing Signatera MRD/monitoring; broad clinical launches and Medicare coverage expansions reported (company investor updates). | |
| Roche Diagnostics | Roche Diagnostics Division sales CHF 14.324 billion (2024) — Elecsys PSA is a core assay in Roche diagnostics portfolio. | |
| Boston Scientific — Rezūm (BPH device) / company sales | Boston Scientific FY2024 net sales $16.747B; prostate-health product Rezūm and SpaceOAR reported strong growth (company Q4/FY highlights). | |
| Teleflex (UroLift via Neotract / portfolio) | Teleflex FY2024 revenue ~ $3,047.3M; UroLift and other urology devices listed among high-growth portfolio products. | |
| PSA / Test market (sample estimates) | PSA/PSA testing market estimates vary: e.g., FutureMarketInsights projects PSA-test industry to ~USD 24.6B by 2035 while other houses show more conservative PSA markets (~USD 0.75–6.3B bases depending on scope). (Multiple PSA-market reports show wide scope variance.) |
Quick caveats & how I selected sources
“Prostate health” is a broad label — different firms include different things (therapeutics, diagnostics, devices, supplements). I deliberately included multiple market-house estimates and company-level datapoints so you can choose the scope that matches your purpose.
Company sales numbers are taken from company financial reports / major news outlets and are shown in the original currency reported (I included the source so you can convert or drill in).
If you’d like I can now (pick one) and I’ll generate it immediately:
CSV of the company datapoints above (company | metric | value | source URL).
One-page PPTX summarizing market-scenarios (broad vs diagnostics-only) + the company table + source appendix.
Narrowed brief that focuses only on (a) therapeutics (drug revenues and pipelines) or (b) diagnostics (PSA / genomic / ctDNA), with a 10-company vendor comparison.
Which output should I create for you now?
Comments
Post a Comment